AR080774A1 - Peptido senal, y su utilizacion para la produccion de proteinas recombinantes - Google Patents
Peptido senal, y su utilizacion para la produccion de proteinas recombinantesInfo
- Publication number
- AR080774A1 AR080774A1 ARP110100877A ARP110100877A AR080774A1 AR 080774 A1 AR080774 A1 AR 080774A1 AR P110100877 A ARP110100877 A AR P110100877A AR P110100877 A ARP110100877 A AR P110100877A AR 080774 A1 AR080774 A1 AR 080774A1
- Authority
- AR
- Argentina
- Prior art keywords
- peptide
- amino acids
- interest
- ala
- production
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 10
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title 1
- 108010076504 Protein Sorting Signals Proteins 0.000 abstract 5
- 235000001014 amino acid Nutrition 0.000 abstract 5
- 150000001413 amino acids Chemical class 0.000 abstract 5
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 235000018102 proteins Nutrition 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 235000005772 leucine Nutrition 0.000 abstract 1
- 150000002614 leucines Chemical class 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Reivindicacion 1: Utilizacion de un péptido senal para la produccion de un polipéptido recombinante de interés en un sistema de expresion, comprendiendo dicho péptido senal por lo menos 12 aminoácidos de formula: (X1)iX2X3X4SX5X6X7, en donde: - X1 es un péptido que contiene de 3 a 6 aminoácidos, i igual a 0 o 1, - X2 es un péptido que contiene de 3 a 9 aminoácidos hidrofobos, - X3 es un péptido que contiene de 3 a 5 aminoácidos, comprendiendo dicho péptido por lo menos 3 leucinas, contiguas o no, - X4 es un péptido que contiene de 2 a 5 aminoácidos elegidos entre Ala, Thr, Ser, GIn, Ile, Met, - X5 es Ala o Val, -X6 es Gin, Asn o His, - X7 es Ala o Cys, con la condicion que, - cuando dicho péptido senal proviene de un precursor natural de una proteína determinada, dicho péptido de interés es diferente de dicha proteína, y - cuando el péptido senal es MAWVWTLLFLMAAAQSAQA, dicho polipéptido de interés no es un anticuerpo anti-CD23, pudiendo cualquier polipéptido de interés estar ligado a uno de dichos péptidos senal para ser secretado en un medio extracelular.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1051905A FR2957598B1 (fr) | 2010-03-17 | 2010-03-17 | Nouveau peptide signal, et son utilisation pour la production de proteines recombinantes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR080774A1 true AR080774A1 (es) | 2012-05-09 |
Family
ID=42670518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110100877A AR080774A1 (es) | 2010-03-17 | 2011-03-17 | Peptido senal, y su utilizacion para la produccion de proteinas recombinantes |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8883450B2 (es) |
| EP (1) | EP2547694B1 (es) |
| JP (1) | JP6000130B2 (es) |
| AR (1) | AR080774A1 (es) |
| CA (1) | CA2789375C (es) |
| DK (1) | DK2547694T5 (es) |
| ES (1) | ES2602044T3 (es) |
| FR (1) | FR2957598B1 (es) |
| WO (1) | WO2011114063A2 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2981661B1 (fr) * | 2011-10-25 | 2015-06-19 | Lfb Biotechnologies | Procede de preparation du facteur h humain |
| FR3012453B1 (fr) | 2013-10-31 | 2015-11-13 | Lab Francais Du Fractionnement | Proteine chimerique dans le traitement de l’amylose |
| FR3016633B1 (fr) | 2014-01-17 | 2018-04-13 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Immunoglobuline anti-toxine du charbon |
| FR3034420A1 (fr) | 2015-03-31 | 2016-10-07 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-cd303 |
| EP3368561B1 (en) * | 2015-10-30 | 2025-09-17 | Medimmune Limited | Prevention of n-terminal truncation in igg light chains |
| FR3075200B1 (fr) * | 2017-12-15 | 2022-12-23 | Lab Francais Du Fractionnement | Variants avec fragment fc ayant une affinite augmentee pour fcrn et une affinite augmentee pour au moins un recepteur du fragment fc |
| US12331091B2 (en) | 2018-12-23 | 2025-06-17 | Taiwan Bio-Manufacturing Corporation | Chimeric signal peptides for protein production |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01240191A (ja) | 1988-02-16 | 1989-09-25 | Green Cross Corp:The | 酵母で機能する新規シグナルペプチドおよびこれを用いた異種蛋白質の分泌発現 |
| FR2636643B1 (fr) | 1988-08-24 | 1990-12-28 | Sanofi Sa | Peptide-signal, sequences d'adn codant pour celui-ci, vecteurs d'expression portant l'une de ces sequences et procede de production periplasmique d'un polypeptide |
| GB9809839D0 (en) * | 1998-05-09 | 1998-07-08 | Glaxo Group Ltd | Antibody |
| FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
| US7425328B2 (en) * | 2003-04-22 | 2008-09-16 | Purdue Pharma L.P. | Tissue factor antibodies and uses thereof |
| FR2861078B1 (fr) | 2003-10-16 | 2007-09-21 | Lab Francais Du Fractionnement | NOUVELLES IgG3 UTILES POUR STIMULER LA PHAGOCYTOSE |
| BRPI0617688A2 (pt) * | 2005-10-21 | 2011-06-07 | Hoffmann La Roche | método para expressão recombinante de um polipeptìdeo |
| DK1989302T3 (en) * | 2006-02-14 | 2018-07-23 | Bp Corp North America Inc | XYLANASES, NUCLEIC ACID CODING THEM AND PROCEDURES FOR THEIR PREPARATION AND USE |
-
2010
- 2010-03-17 FR FR1051905A patent/FR2957598B1/fr active Active
-
2011
- 2011-03-17 EP EP11715936.8A patent/EP2547694B1/fr active Active
- 2011-03-17 US US13/583,337 patent/US8883450B2/en active Active
- 2011-03-17 AR ARP110100877A patent/AR080774A1/es unknown
- 2011-03-17 CA CA2789375A patent/CA2789375C/fr not_active Expired - Fee Related
- 2011-03-17 ES ES11715936.8T patent/ES2602044T3/es active Active
- 2011-03-17 JP JP2012557592A patent/JP6000130B2/ja active Active
- 2011-03-17 WO PCT/FR2011/050544 patent/WO2011114063A2/fr not_active Ceased
- 2011-03-17 DK DK11715936.8T patent/DK2547694T5/da active
Also Published As
| Publication number | Publication date |
|---|---|
| US8883450B2 (en) | 2014-11-11 |
| WO2011114063A2 (fr) | 2011-09-22 |
| JP6000130B2 (ja) | 2016-09-28 |
| JP2013521794A (ja) | 2013-06-13 |
| DK2547694T5 (da) | 2019-07-29 |
| CA2789375C (fr) | 2019-05-07 |
| FR2957598A1 (fr) | 2011-09-23 |
| WO2011114063A3 (fr) | 2012-01-12 |
| DK2547694T3 (en) | 2016-12-05 |
| ES2602044T3 (es) | 2017-02-17 |
| EP2547694A2 (fr) | 2013-01-23 |
| EP2547694B1 (fr) | 2016-08-17 |
| CA2789375A1 (fr) | 2011-09-22 |
| US20130122546A1 (en) | 2013-05-16 |
| FR2957598B1 (fr) | 2015-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR080774A1 (es) | Peptido senal, y su utilizacion para la produccion de proteinas recombinantes | |
| PE20190352A1 (es) | Proteinas de fusion gdf 15 y usos de estas | |
| ES2534744T3 (es) | Plasmina modificada de forma recombinante | |
| BR112018000660A2 (pt) | peptídeos anti-inflamatórios e seu uso | |
| ES2545895T3 (es) | Proteína de fusión anticancerígena | |
| PE20191033A1 (es) | PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa) | |
| EA201592306A1 (ru) | Вакцины против вируса гриппа и их применения | |
| PE20121721A1 (es) | Analogo peptidico de oxintomodulina | |
| FI3737399T3 (fi) | ATF5-peptidivariantit ja niiden käytöt | |
| ES2676499T3 (es) | Proteínas de fusión Fc que comprenden nuevos enlazadores o disposiciones | |
| CO2017002166A2 (es) | Proteínas de fusión de interleucina 2 / receptor de interleucina-2 alfa | |
| PL397167A1 (pl) | Przeciwnowotworowe bialko fuzyjne | |
| PE20091214A1 (es) | Sintesis de peptidos insulinotropicos utilizando una combinacion de tecnicas en fase solida y en solucion | |
| CL2017000200A1 (es) | Célula huésped mejorada para producir proteinas | |
| AR064555A1 (es) | Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo | |
| PE20140617A1 (es) | Alfa glucosidasa acida modificada con procesamiento acelerado | |
| JP2015504052A5 (es) | ||
| HRP20180012T1 (hr) | Antikancerogeni fuzijski protein | |
| CO6430475A2 (es) | Polipéptidos que tienen actividad de celulasa | |
| AR065074A1 (es) | Peptidos de senalizacion | |
| CA2839298C (en) | Anti-inflammatory pharmaceutical products | |
| PE20200514A1 (es) | Compuestos de mic-1 y usos de estos | |
| MX2022003531A (es) | Polipeptidos de fusion dap10/dap12. | |
| BRPI0715331B8 (pt) | polipeptídeo que compreende uma porção n-terminal e uma porção c-terminal, e uso do mesmo | |
| PE20220500A1 (es) | POLIPEPTIDO DE FUSION QUE COMPRENDE LA REGION Fc DE INMUNOGLOBULINA Y GDF15 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |